Web Exclusives

CHICAGO—In a phase 1 study in advanced non–small-cell lung cancer (NSCLC) deemed worthy of a presentation at the American Society of Clinical Oncology’s 46th annual meeting plenary session, a multinational group of investigators reported improved survival with an oral investigational agent still unfamiliar to most oncologists.
 

As health plans grapple with the rapidly rising cost of oncology medications and a “buy and bill” system that does not work for physicians or for the plans, they are seeking new strategies for providing these life-saving drugs to their members and for freeing up oncology and hematology practices to focus solely on caring for patients, not managing a pharmacy.

Oncology Nurses Play a Pivotal Role in Amyloidosis Management

Although primary amyloidosis is rare, oncology nurses have a broad range of responsibilities in managing patients who develop this disorder, researchers said.

CEP17 Breast Cancer Tumors Are More Likely to Respond to Anthracyclines

BARCELONA—Breast cancer patients with the chromosome enumeration probe 17 (CEP17) alpha satellite abnormality are more likely to have good outcomes from chemotherapy involving anthracycline antibiotics than women without the abnormality, according to new data released at the Seventh European Breast Cancer Conference.

President Obama guaranteed Americans that after health reform became law they could keep their insurance plans and their doctors. It’s clear that this promise cannot be kept. Insurers and physicians are already reshaping their businesses as a result of Mr. Obama’s plan.

The discipline of breast surgery, like many specialties, has moved toward a minimally invasive approach to local therapy. Radical surgery had previously been the standard; however, surgical approaches continue to evolve as we gather more data about the oncologic safety of less invasive procedures. In addition, we are placing more emphasis on targeted therapy, and surgery is an integrated portion of patient care.

In the first head-to-head comparison of targeted oral tyrosine kinase inhibitors as initial treatment for early-stage chronic myeloid leukemia (CML), molecular and cytogenetic remissions were more common with nilotinib compared with imatinib, the previous standard for treating early-stage CML, said Giuseppe Saglio, MD.

Page 20 of 20
Results 191 - 199 of 199